Sign in Subscribe
Cancer

HER2+ Gastric Cancer Market Surges as FDA Approvals and Late-Stage Clinical Trials Drive Paradigm Shift

Strategic Insights

— 2 min read

The HER2+ gastric cancer market is expected to experience significant growth, driven by a rising incidence of the disease, improved diagnostic protocols, and expanding therapeutic options. Recently, the FDA has approved several therapies, including ENHERTU, OPDIVO, trastuzumab, KEYTRUDA, and AIDIXI, which are further fueling the market growth. Additionally, late-stage clinical trials, such as the DESTINY-Gastric04 trial, have demonstrated significant survival benefits for trastuzumab deruxtecan in the second-line setting, establishing it as a new standard of care for second-line treatment in HER2-positive metastatic gastric cancer. Emerging therapies, such as Evorpacept, Zanidatamab, IAM1363, ELVN 002, ARX788, and Rilvegostomig, are also in development and are expected to transform the treatment landscape for HER2-positive gastric cancer.

Key Takeaways:

  • The HER2+ gastric cancer market is projected to grow significantly, driven by a rising incidence, improved diagnostic protocols, and expanding therapeutic options.
  • The FDA has recently approved several therapies, including ENHERTU, OPDIVO, trastuzumab, KEYTRUDA, and AIDIXI, which are further fueling the market growth.
  • Late-stage clinical trials, such as the DESTINY-Gastric04 trial, have demonstrated significant survival benefits for trastuzumab deruxtecan in the second-line setting, establishing it as a new standard of care for second-line treatment in HER2-positive metastatic gastric cancer.
  • Emerging therapies, such as Evorpacept, Zanidatamab, IAM1363, ELVN 002, ARX788, and Rilvegostomig, are also in development and are expected to transform the treatment landscape for HER2-positive gastric cancer.
  • The gastric cancer incidence varies considerably across different geographic regions, with Eastern Asian countries, including Japan, reporting the highest incidence rates.
  • The US accounts for a notable proportion of gastric cancer cases, representing 1.5% of all new cancer diagnoses each year.
  • As per DelveInsight's estimates, the HER2+ gastric cancer market is projected to grow significantly from 2024 to 2034.
  • Several pipeline drugs for HER2+ gastric cancer, including Evorpacept, Zanidatamab, IAM1363, ELVN 002, ARX788, and Rilvegostomig, are in development.

Statistics:

  • The gastric cancer incidence varies from 1.5% to 3.3% in Eastern Asian countries, including Japan.
  • The US accounts for 1.5% of all new cancer diagnoses each year.
  • As per DelveInsight's estimates, the HER2+ gastric cancer market is projected to grow at a CAGR of 20.3% from 2024 to 2034.
  • The market size is expected to reach $2.6 billion by 2034.
  • The US and Japan are expected to account for the largest share of the market, representing 30.3% and 23.4% of the total market size, respectively.

Sources:

  • DelveInsight's "HER2+ Gastric Cancer - Market Insight, Epidemiology And Market Forecast - 2034"
  • FDA approval of ENHERTU (Daiichi Sankyo and AstraZeneca), OPDIVO (Bristol Myers Squibb), trastuzumab (Roche), KEYTRUDA (Merck & Co., Inc.), and AIDIXI (RemeGen)
  • DESTINY-Gastric04 trial results presented at the 2025 ASCO Annual Meeting
  • DELVEINSIGHT abilities and services

Read more